Ambulatory flexible ureteroscopy under local anaesthesia for UTUC surveillance
Official title: Flexible Ureterorenoscopy for Surveillance of Upper Tract Urothelial Carcinoma-A Pilot Study
Run by Chinese University of Hong Kong · NCT06848868 · Data updated 2026-11-12
This pilot will try flexible ureteroscopy under local anaesthesia to see if it is safe and workable for people needing surveillance after kidney-sparing surgery for upper tract urothelial carcinoma.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 2 sites (Hong Kong and 1 other locations) |
| Status | Recruiting |
| Started | July 1, 2025 |
| Main results expected | June 30, 2026 |
| Study ends | June 30, 2029 |
| Registry record updated | September 15, 2025 |
| Trial ID | NCT06848868 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) who can give informed consent, have undergone kidney-sparing surgery for upper tract urothelial carcinoma, can safely pause anticoagulation, and do not have lidocaine allergy or relevant upper tract structural abnormalities are ideal candidates.
✕Probably not a fit
Patients who cannot discontinue anticoagulant or antiplatelet therapy, who have lidocaine allergy, significant upper tract structural abnormalities, or who require therapeutic procedures under general anaesthesia are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective single-arm pilot will enroll up to 10 adults who previously had kidney-sparing surgery for upper tract urothelial carcinoma to receive flexible ureteroscopy performed under local anaesthesia in an ambulatory urology centre. The primary outcome is procedural technical success, and secondary outcomes include 30-day complication and readmission rates, cost analysis, and patient-reported outcomes. Pre-procedure urine cultures with targeted antibiotics for bacteriuria and stopping anticoagulants per local guidelines will be used to reduce infection and bleeding risk, and procedures will use transurethral lidocaine jelly with optional intravenous sedation. Procedural details, adverse events and patient-reported measures will be collected by experienced urologists to document safety and practicality of outpatient surveillance.
Why it matters
Potential benefit: If successful, this could allow outpatient UTUC surveillance without general anaesthesia, reducing recovery time, cost, and anaesthesia-related risks.
How similar studies have gone: Office-based or awake ureteroscopy techniques have been reported in small series, but there is limited published evidence specifically validating ambulatory flexible ureteroscopy under local anaesthesia for UTUC surveillance.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged 18 years or older 2. Capable of giving informed consent 3. Having undergone an kidney-sparing surgery (endoscopic operation or segmental ureterectomy) Exclusion Criteria: 1. Allergy to transurethral lidocaine jelly 2. On anticoagulation or anti-platelet medication with contraindications for cessation prior to the procedure 3. Structural abnormalities in the upper urinary tract on the intended side of examination
Where it's running
-
Prince of Wales Hospital
Hong Kong, Hong Kong Recruiting -
The Chinese University of Hong Kong
Hong Kong, Hong Kong Not yet recruiting
Study contacts
- Study coordinator: Jeremy Teoh Teoh, FHKAM, FRCS, MD
- Email: jeremyteoh@surgery.cuhk.edu.hk
- Phone: +852 35051663
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Urinary Cell-Free DNA Test for Urothelial Cancer Origin
This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.
-
Blood test for detecting tumor DNA in bladder and upper tract cancer
A blood test that looks for tumor DNA in people with muscle-invasive bladder cancer or upper tract urothelial cancer is being tested to see if it matches what’s found in tumor tissue and if it can help track recurrence or remission over two years.
-
Non-invasive urine test to screen for urothelial cancer in adults with blood in urine
A noninvasive urine test is being used to see if it can correctly identify urothelial cancer in adults who have blood in urine and a suspicious imaging finding.
-
Flexible ureteroscopy to monitor upper tract urothelial carcinoma
A small, forward-looking study will test whether doing flexible ureteroscopy under local anesthesia is safe and feasible for people who have had kidney-sparing treatment for upper tract urothelial carcinoma.
-
Disitamab Vedotin Plus Radiotherapy for HER2-Expressing Upper Tract Urothelial Carcinoma After Surgery
This study tests whether disitamab vedotin with radiotherapy can improve outcomes for people with HER2-expressing upper tract urothelial carcinoma after radical surgery who can’t receive cisplatin.
-
Dual-target Nectin-4 and HER2 CAR-NK therapy for advanced urothelial carcinoma
This treatment will try dual-target CAR-NK cells that recognize Nectin‑4 and HER2 in adults with relapsed or metastatic urothelial carcinoma after standard therapies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.